NDC 0078-0883

ADAKVEO

Crizanlizumab

ADAKVEO is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Crizanlizumab.

• Product ID: 0078-0883_570aa3b2-0dac-4c50-ba49-ba85e5b2227a
• NDC: 0078-0883
• Product Type: Human Prescription Drug
• Proprietary Name: ADAKVEO
• Generic Name: Crizanlizumab
• Dosage Form: Injection
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2019-11-15
• Marketing Category: BLA / BLA
• Application Number: BLA761128
• Labeler Name: Novartis Pharmaceuticals Corporation
• Substance Name: CRIZANLIZUMAB
• Active Ingredient Strength: 10 mg/mL
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 0078-0883-61

10 mL in 1 VIAL, GLASS (0078-0883-61)

• Marketing Start Date: 2019-11-15
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0078-0883-61 [00078088361]

ADAKVEO INJECTION

• Marketing Category: BLA
• Application Number: BLA761128
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2019-11-15

Drug Details

Active Ingredients

Ingredient	Strength
CRIZANLIZUMAB	10 mg/mL